10 Best Pharma Dividend Stocks To Buy

Published on October 29, 2022 at 1:03 pm by Hamna Asim in Hedge Funds, News

In this article, we discuss 10 best pharma dividend stocks to buy. If you want to see more stocks in this selection, check out 5 Best Pharma Dividend Stocks To Buy.

As per a Bloomberg report dated September 12, the global bio-pharma market was valued at $274.10 billion in 2020 and is forecasted to reach $703.28 billion by 2027 with a CAGR of 12.5% over the forecast period. The factors which will contribute to the growth of the pharma sector include the heightening prevalence of chronic diseases, increasing investment in research and development, and the growing pharmaceutical innovations. The global bio-pharma market will witness continuous growth on the back of higher need for vaccines with new diseases being discovered all over the world.

The outlook for the pharma industry remains positive for 2023. The industry will potentially exceed $1 trillion by next year, given that multiple last-stage clinical trials are set to be approved and hundreds of new products will be patented in 2023 and beyond. Some key trends which will shape the pharmaceutical industry in 2023 include the use of artificial intelligence, the acceptance of cannabidiol (CBD) for medical purposes, precision medicine, the use of blockchain technology in the pharmaceutical industry, smaller manufacturing facilities, digitization, state-mandated discounts and rebates, and an increased focus on research and development. Nearly 38% of market experts anticipate big data to have the highest impact on the pharmaceutical industry.

Investors who want to benefit from the growing pharma industry, and are seeking dividend-paying firms for their portfolios, can monitor stocks like Amgen Inc. (NASDAQ:AMGN), Bristol-Myers Squibb Company (NYSE:BMY), and Merck & Co., Inc. (NYSE:MRK).

Our Methodology

We selected the following pharma dividend stocks based on positive analyst coverage, strong business fundamentals, and solidity of dividend profiles. The dividend yields as of October 27 have been mentioned. We have assessed the hedge fund sentiment from Insider Monkey’s database of 895 elite hedge funds tracked as of the end of the second quarter of 2022.

Pixabay/Public Domain

Best Pharma Dividend Stocks To Buy

10. GSK plc (NYSE:GSK)

Number of Hedge Fund Holders: 34

Dividend Yield as of October 27: 5.59%

GSK plc (NYSE:GSK) was founded in 1715 and is headquartered in Brentford, the United Kingdom. The company engages in the development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products. It operates through four segments – Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company’s dividend yield on October 27 came in at 5.59%.

On October 20, GSK plc (NYSE:GSK) reported that its vaccine Shingrix was able to offer at least a decade of protection against shingles after initial vaccination in adults aged 50 years and over. Vaccine efficacy was 97% in individuals 50 years and older and 91% in adults 70 years and above over a follow-up period of roughly four years.

Morgan Stanley analyst Mark Purcell on October 12 raised the price target on GSK plc (NYSE:GSK) to 1,650 GBp from 1,550 GBp and maintained an Equal Weight rating on the shares.

According to Insider Monkey’s second quarter database, 34 hedge funds were long GSK plc (NYSE:GSK), compared to 33 funds in the prior quarter. Ken Fisher’s Fisher Asset Management featured as the biggest stakeholder of the company, with 19.6 million shares worth $851.80 million.

In addition to Amgen Inc. (NASDAQ:AMGN), Bristol-Myers Squibb Company (NYSE:BMY), and Merck & Co., Inc. (NYSE:MRK), GSK plc (NYSE:GSK) is one of the best pharma dividend stocks to invest in.

9. Walgreens Boots Alliance, Inc. (NASDAQ:WBA)

Number of Hedge Fund Holders: 40

Dividend Yield as of October 27: 5.34%

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) is based in Deerfield, Illinois, operating as an integrated healthcare, pharmacy, and retailer in the United States, the United Kingdom, Germany, and internationally. The company has three segments – U.S. Retail Pharmacy, International, and U.S. Healthcare. Walgreens Boots Alliance, Inc. (NASDAQ:WBA) is one of the best dividend stocks to invest in.

On October 13, Walgreens Boots Alliance, Inc. (NASDAQ:WBA) posted a FQ4 non-GAAP EPS of $0.80 and a revenue of $32.45 billion, outperforming estimates by $0.03 and $280 million, respectively. For FY2023, the firm expects adjusted EPS of $4.45 to $4.65 as resilient core business growth is more than offset by slowing 2022 COVID-19 execution and currency headwinds, versus the market consensus of $4.49.

Deutsche Bank analyst George Hill raised the price target on Walgreens Boots Alliance, Inc. (NASDAQ:WBA) to $41 from $38 and maintained a Hold rating on the shares on October 25. The analyst’s primary takeaway from the latest earnings call is that the speed of decline in the pharmacy sector may have troughed and that Walgreens Boots Alliance, Inc. (NASDAQ:WBA) may be in a position to gain market share.

According to the second quarter database of Insider Monkey, 40 hedge funds were bullish on Walgreens Boots Alliance, Inc. (NASDAQ:WBA), compared to 38 funds in the preceding quarter. Stephen Dubois’ Camber Capital Management is a significant position holder in the company, with 2.82 million shares worth $107 million.

Here is what Aristotle Capital Management Global Equity has to say about Walgreens Boots Alliance, Inc. (NASDAQ:WBA) in its Q1 2022 investor letter:

“We first invested in Walgreens Boots Alliance in early 2013. Over our holding period, Walgreens merged with U.K.-based Boots Alliance, establishing itself as a global leading retail pharmacy chain. CEO Stefano Pessina set the company on a path of pursuing strategic partnerships (as opposed to vertical integration deals) to increase store traffic and to, over time, transform the business into a neighborhood health destination around a more modern pharmacy. Using its strong FREE cash flow generation, the company ramped up its investments in technology, aiming to accelerate the digitalization of health information. Mr. Pessina was not successful, however, at turning around the firm’s U.S. retail segment and had to deal with increasing prescription drug reimbursement pressures. He stepped down as CEO in 2020, and in 2021, Roz Brewer took the reins of the firm. We admire Ms. Brewer’s impressive track record at companies that include Starbucks (NASDAQ:SBUX) and Walmart (Sam’s Club). However, given management’s decision to divest core cash-generative businesses and redeploy capital to embryonic healthcare startups, we prefer to step aside while we follow the company’s progress.”

8. Cardinal Health, Inc. (NYSE:CAH)

Number of Hedge Fund Holders: 44

Dividend Yield as of October 27: 2.62%

Cardinal Health, Inc. (NYSE:CAH) operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty drugs, and over-the-counter healthcare and consumer products. On September 15, PayrHealth announced a collaboration with Cardinal Health, Inc. (NYSE:CAH) to help the latter simplify payor contracting and optimize financial performance. It is one of the best dividend stocks to consider.

On August 29, UBS analyst Kevin Caliendo raised the price target on Cardinal Health, Inc. (NYSE:CAH) to $78 from $61 and maintained a Buy rating on the shares. The company’s Pharma segment and the potential for significant capital deployment will support the stock, the analyst told investors. He further cited Cardinal Health, Inc. (NYSE:CAH)’s “cleaner” balance sheet and estimated a forward free cash flow yield of about 10% before dividends.

According to Insider Monkey’s data, 44 hedge funds were long Cardinal Health, Inc. (NYSE:CAH) at the end of June 2022, compared to 38 funds in the prior quarter. Richard S. Pzena’s Pzena Investment Management is the leading position holder in the company, with 2.9 million shares worth $151.35 million.

7. AstraZeneca PLC (NASDAQ:AZN)

Number of Hedge Fund Holders: 47

Dividend Yield as of October 27: 3.29%

AstraZeneca PLC (NASDAQ:AZN) is headquartered in Cambridge, the United Kingdom, and the company is focused on the discovery, manufacture, and commercialization of prescription medicines. AstraZeneca PLC (NASDAQ:AZN) is one of the best dividend stocks to invest in, with the stock yielding 3.29% as of October 27. Invitae Corporation (NYSE:NVTA) announced a partnership with AstraZeneca PLC (NASDAQ:AZN) on October 27, where the latter can use Invitae’s Citizen natural history data in a retrospective and prospective study of patients diagnosed with cholangiocarcinoma, a rare bile duct cancer.

On October 19, Berenberg analyst Luisa Hector maintained a Buy rating on AstraZeneca PLC (NASDAQ:AZN) but lowered the price target on the shares to 118 GBp from 120 GBp.

Among the hedge funds tracked by Insider Monkey, 47 funds reported owning stakes worth $4.9 billion in AstraZeneca PLC (NASDAQ:AZN) at the end of June 2022, compared to 45 funds in the earlier quarter worth $4.5 billion. Ken Fisher’s Fisher Asset Management held the leading position in the company, comprising 21.3 million shares worth $1.4 billion.

Here is what Baron Funds specifically said about AstraZeneca PLC (NASDAQ:AZN) in its Q3 2022 investor letter:

“AstraZeneca PLC (NASDAQ:AZN) is a global pharmaceutical company focused on oncology, respiratory, cardiovascular, and metabolism drugs. Despite incremental positive news flow, shares were hurt by the broader flight out of European stocks and the decline in the British Pound that started late in the quarter. We retain conviction in AstraZeneca given its best-in-class growth profile combined with its strong pipeline and commercial launch characteristics. We highlight breast cancer drugs Enhertu and Dato-DXd as two promising near-term opportunities.”

6. Amgen Inc. (NASDAQ:AMGN)

Number of Hedge Fund Holders: 55

Dividend Yield as of October 27: 2.90%

Amgen Inc. (NASDAQ:AMGN) is a California-based manufacturer of human therapeutics, focused on therapeutic areas such as inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. On October 18, ChemoCentryx shareholders largely approved Amgen Inc. (NASDAQ:AMGN)’s $3.7 billion acquisition of the company. The acquisition will strengthen Amgen’s product pipeline further.

On October 11, Morgan Stanley analyst Matthew Harrison upgraded Amgen Inc. (NASDAQ:AMGN) to Overweight from Equal Weight with a price target of $279, up from $257. The analyst sees “underappreciated upside” in the company’s mid-term pipeline. Amgen Inc. (NASDAQ:AMGN) has defensive positioning in the present macro backdrop, with “attractive” short-term options of AMG133 for obesity and the biosimilar Amjevita launch, the analyst told investors in a research note.

According to Insider Monkey’s data, 55 hedge funds were bullish on Amgen Inc. (NASDAQ:AMGN) at the end of the second quarter of 2022, compared to 56 funds in the last quarter. John Overdeck and David Siegel’s Two Sigma Advisors is the largest position holder in the company, with 1.66 million shares worth $404.3 million.

Like AbbVie Inc. (NYSE:ABBV), Bristol-Myers Squibb Company (NYSE:BMY), and Merck & Co., Inc. (NYSE:MRK), Amgen Inc. (NASDAQ:AMGN) is one of the best dividend stocks to consider.

Here is what Aristotle Capital specifically said about Amgen Inc. (NASDAQ:AMGN) in its Q2 2022 investor letter:

“Amgen Inc. (NASDAQ:AMGN), the pharmaceutical company focused on biotechnology-based therapeutics, was also a top contributor for the quarter. The company reported solid results, with a variety of products, such as bone-strengthening drugs Prolia and EVENITY, contributing to overall revenue growth. Amgen continued to increase the market share for cholesterol drug Repatha (a catalyst we had originally identified), delivering record quarterly sales as the drug’s usage expands with high-risk patients who have not yet had a cardiovascular event, and as barriers for prescribers, healthcare systems and patients are removed. In addition, we believe the company is poised to gain market share with its biosimilars (akin to generic versions of biologic drugs), also a previously identified catalyst. Biosimilars accounted for over $2 billion in revenue in 2021, and we believe this has the potential to more than double by the end of the decade, accelerated by six additional biosimilars (for a total of 11 products on the market). This includes the upcoming launch in the U.S. of arthritis treatment Amjetiva in January 2023. Meanwhile, the company is advancing its robust pipeline of early- and late-stage assets, with several phase III results due this year. These developments have caused us to remain enthusiastic about Amgen’s ability to build on its decades of success developing novel treatments using biopharmaceuticals.”

Click to continue reading and see 5 Best Pharma Dividend Stocks To Buy.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on May 1, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

Published on May 2, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up